Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yangxue Qingnao Pills in Mild to Moderate Alzheimer's Disease
NCT04780399Phase 2Unknown
- Sponsor
- Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
- Start
- Nov 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Yangxueqingnao in Alzheimer's disease (AD) (3 arms), sponsored by Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine. Primary endpoints: Alzheimer's Disease Assessment Scale-Cognition Subscale at 48 weeks and Clinical Dementia Rating Scale-Sum of Boxes at 48 weeks. Status: unknown.
02
Drugs
Yangxueqingnao
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04780399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04780399.